C V Therapeutics' angina drug filings accepted (PharmaBiz)
Biopharmaceutical company, CV Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) as well as its new drug application (NDA) for chronic angina drug Ranexa.
Original post: C V Therapeutics' angina drug filings accepted (PharmaBiz)